Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
J Alzheimers Dis
; 100(1): 193-205, 2024.
Article
en En
| MEDLINE
| ID: mdl-38848176
ABSTRACT
Background:
The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).Objective:
To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.Methods:
We included baseline data of Nâ=â338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aß42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.Results:
We identified three distinct participant clusters based on presented symptoms. The highest rate of A+âparticipants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+26.6%) and a cluster of participants with overall few symptoms (A+19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aß42/ptau181 ratio compared to those with neither SCD nor OBJ.Conclusions:
The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Biomarcadores
/
Péptidos beta-Amiloides
/
Enfermedad de Alzheimer
/
Disfunción Cognitiva
/
Pruebas Neuropsicológicas
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2024
Tipo del documento:
Article